Exploration of polymethacrylate and Hypromellose for the development of a non-sulfhydryl ACE inhibitor mucoadhesive system using Box-Behnken design: in-vitro and ex-vivo evaluation

References

• Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237. Available from: http://dx.doi.org/10.1038/s41581-019-0244-2.
   PubMed Web of Science ®Google Scholar
• WHO. Hypertension WHO [Internet]. Hypertension. 2021. p. 12–14. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension.
   Google Scholar
• Smolensky MH, Haus E. Circadian rhythms and clinical medicine with applications to hypertension. Am J Hypertens. 2001;14:280–290.
   PubMedGoogle Scholar
• Hermida RC, Ayala DE, Calvo C, et al. Chronotherapy of hypertension: administration-time-dependent effects of treatment on the circadian pattern of blood pressure. Adv Drug Deliv Rev. 2007;59(9–10):923–939.
   PubMed Web of Science ®Google Scholar
• Smolensky MH, Hermida RC, Portaluppi F, et al. Chronotherapeutics in the treatment of hypertension. Hypertension. 2005;:51:530–542.
   PubMedGoogle Scholar
• Sokar MS, Hanafy AS, El-Kamel AH, et al. Pulsatile core-in-cup valsartan tablet formulations: in vitro evaluation. Asian J Pharm Sci. 2013;8(4):234–243. Available from: http://dx.doi.org/10.1016/j.ajps.2013.09.006
   Google Scholar
• Lomas J, Anderson GM, Domnick-Pierre K, et al. The new England journal of medicine downloaded from nejm.org at PENN STATE UNIVERSITY on november 25, 2015. For personal use only. No other uses without permission. From the NEJM archive. Copyright © 2010 Massachusetts medical society. All rights reserved. N Engl J Med. 1989;321(19):1306–1311.
   PubMed Web of Science ®Google Scholar
• Weber M. Effect of perindopril erbumine, an angiotensin converting enzyme inhibitor (ACE-I), on blood pressure in patients with mild to moderate hypertension – a large AceonS community trial (ACT) with 8083 patients. Am J Hypertens. 2002;15(4):A41.
   Google Scholar
• Ölçer M, Ölçer A, Ince I, et al. Development and in vitro/in vivo evaluation of immediate release perindopril tablets. Pharm Dev Technol. 2015;20(6):684–693.
   PubMed Web of Science ®Google Scholar
• Bunag R. Perindopril. 2007;2:1–3.
   Google Scholar
• Morgan T, Anderson A, Jones E. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens. 1997;15(2):205–211.
   PubMedGoogle Scholar
• Pandav S, Naik J. Sustained release of ramipril from ammonio methacrylate copolymer matrix prepared by high pressure homogenizer. Int J Pharm Pharm Sci. 2014;6:349–353.
   Google Scholar
• Clark LT. Safety profile of perindopril PERINDOPRIL in PATIENTS WITH. Am J Cardiol. 2001;88(7):36–40.
   Google Scholar
• Satyabrata B, Ellaiah P, Chandan M, et al. Design and in vitro evaluation of mucoadhesive buccal tablets of perindopril prepared by sintering technique. Asian J Pharm Clin Res. 2010;3:4–10.
   Google Scholar
• Ratnaparkhi Mukesh P, Jagadale Sachin S, Patil Pradeep S, et al. Formulation development and evaluation of taste masked orally disintegrating tablets of perindopril erbumine by direct compression method. Int J Drug Dev Res. 2012;4:374–394.
   Google Scholar
• Grover I, Agarwal G. Formulation and evaluation of sublingual tablets of perindopril. J Sci Ind Res. 2012;71:413–417.
   Google Scholar
• Dorniani D, Hussein MB, Kura AU, et al. Sustained release of perindopril erbumine from its chitosan-coated magnetic nanoparticles for biomedical applications. Int J Mol Sci. 2013;14(12):23639–23653.
   PubMedGoogle Scholar
• Al Ali SHH, Al-Qubaisi M, Hussein MZ, et al. Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite. Int J Nanomedicine. 2012;7:2129–2141.
   PubMed Web of Science ®Google Scholar
• Sica DA. Dosage considerations with perindopril for systemic hypertension. Am J Cardiol. 2001;88(7):13–18.
   Google Scholar
• Georgy KR, Farid RM, Latif R, et al. A new design for a chronological release profile of etodolac from coated bilayer tablets: in-vitro and in-vivo assessment. J Adv Res. 2019;15:37–47. Available from: https://doi.org/10.1016/j.jare.2018.08.003.
   PubMedGoogle Scholar
• Jeswani G, Chablani L, Gupta U, et al. Development and optimization of paclitaxel loaded eudragit/PLGA nanoparticles by simplex lattice mixture design: exploration of improved hemocompatibility and in vivo kinetics. Biomed Pharmacother. 2021;144:112286. Available from: https://doi.org/10.1016/j.biopha.2021.112286.
   PubMed Web of Science ®Google Scholar
• Duncan QM, Craig MR. Thermal analysis of pharmaceuticals. 1st ed. Boca Raton, Florida: CRC Press; 2006.
   Google Scholar
• Maheshwari R, Todke P, Kuche K, et al. Micromeritics in pharmaceutical product development. Dos. Form Des. 2018; 17, Considerations Vol. I, 599–635
   Google Scholar
• Rao * Bk JS. 3D blade root shape optimization. IMechE London, UK: Woodhead Publishing; 2012. Available from: https://www.sciencedirect.com/science/article/pii/B9780857094520500141.
   Google Scholar
• Navamanisubramanian R, Nerella R, Duraipandian C, et al. Quality by design approach for optimization of repaglinide buccal tablets using Box-Behnken design. Futur J Pharm Sci. 2018;4(2):265–272. Available from: https://doi.org/10.1016/j.fjps.2018.10.002.
   Google Scholar
• Bezerra MA, Santelli RE, Oliveira EP, et al. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta. 2008;76(5):965–977. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0039914008004050.
   PubMed Web of Science ®Google Scholar
• Candioti LV, De Zan MM, Cámara MS, et al. Experimental design and multiple response optimization. Using the desirability function in analytical methods development. Talanta [Internet]. 2014;124:123–138. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0039914014000459.
   PubMed Web of Science ®Google Scholar
• N Politis, Stavros, Colombo, Paolo, Colombo, Gaia, M Rekkas, Dimitrios,. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017;43(6):889–901. Available from: https://doi.org/10.1080/03639045.2017.1291672.
   PubMed Web of Science ®Google Scholar
• Fukuda IM, Pinto CFF, Moreira CDS, et al. Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD). Brazilian J Pharm Sci. 2018;54:1–16.
   Google Scholar
• Patra CN, Priya R, Swain S, et al. Pharmaceutical significance of Eudragit: a review. Futur J Pharm Sci. 2017;3(1):33–45.
   Web of Science ®Google Scholar
• Verma PRP, Banu V. Sustained release of theophylline from Eudragit RLPO and RSPO tablets. Drug Dev Ind Pharm. 1996;22(12):1243–1247.
   Web of Science ®Google Scholar
• Ceballos A, Cirri M, Maestrelli F, et al. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Farmaco. 2005;60(11–12):913–918.
   PubMedGoogle Scholar
• Jawed S, Satish CS. Exploration of parteck ® SRP 80 and hypromellose for chronomodulated release of LTD4 receptor antagonist and statistical optimization using Central composite design. AAPS PharmSciTech. 2022;23(7):1–13. Available from: https://doi.org/10.1208/s12249-022-02415-5.
   Google Scholar
• Evonik markets new enteric protected ready-to-fill capsules for fast, high-performance drug development [Internet]2021. Available from: https://healthcare.evonik.com/en/evonik-markets-new-enteric-protected-ready-to-fill-capsules-for-fast-high-performance-drug-developme-158686.html.
   Google Scholar
• Bohrey S, Chourasiya V, Pandey A. Polymeric nanoparticles containing diazepam: preparation, optimization, characterization, in-vitro drug release and release kinetic study. Nano Converg. 2016;3:3–9.
   PubMed Web of Science ®Google Scholar
• Habashy R, Khoder M, Zhang S, et al. An innovative wax-based enteric coating for pharmaceutical and nutraceutical oral products. Int J Pharm. 2020;591:119935. Available from: https://doi.org/10.1016/j.ijpharm.2020.119935.
   PubMedGoogle Scholar
• Singh I, Rana V. Iron oxide induced enhancement of mucoadhesive potential of Eudragit RLPO: formulation, evaluation and optimization of mucoadhesive drug delivery system. Expert Opin Drug Deliv. 2013;10(9):1179–1191.
   PubMed Web of Science ®Google Scholar
• Ofokansi KC, Kenechukwu FC. Formulation development and evaluation of drug release kinetics from Colon-Targeted ibuprofen tablets based on Eudragit RL 100-Chitosan interpolyelectrolyte complexes. ISRN Pharm. 2013;2013:1–8.
   Google Scholar
• Turanlı Y, Acartürk F. Fabrication and characterization of budesonide loaded Colon-specific nanofiber drug delivery systems using anionic and cationic polymethacrylate polymers. J Drug Deliv Sci Technol. 2021;63:102511. Available from: https://doi.org/10.1016/j.jddst.2021.102511
   Web of Science ®Google Scholar
• Roni MA, Kibria G, Jalil R. Formulation and in vitro evaluation of alfuzosin extended release tablets using directly compressible Eudragit. Indian J Pharm Sci. 2009;71(3):252–258.
   PubMedGoogle Scholar
• Roy H, Brahma C, Nandi S, et al. Formulation and design of sustained release matrix tablets of metformin hydrochloride: influence of hypromellose and polyacrylate polymers. Int J Appl Basic Med Res. 2013;3(1):55–63.
   PubMedGoogle Scholar
• Martínez-Olivo AO, Zamora-Gasga VM, Medina-Torres L, et al. Formulation of double emulsions of mango seed extract (Mangifera indica L.) “Ataulfo” incorporated into a mango by-product flour drink: release kinetics, antioxidant capacity, and inhibition of cyclooxygenases. Food Hydrocoll Heal. 2023;3:100120.
   Google Scholar
• Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm – Drug Res. 2010;67:217–223.
   PubMed Web of Science ®Google Scholar
• Shagufta K, Kishor C, Dilesh S, et al. Formulation and release behavior of sustained release stavudine hydrochloride matrix tablet containing hydrophilic and hydrophobic polymers. Int J Drug Dev Res. 2013;5:32–37.
   Google Scholar
• Kuksal A, Tiwary AK, Jain NK, et al. Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSciTech. 2006;7(1):E1–E9.
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Daniels R. A novel test system for the evaluation of oral mucoadhesion of fast disintegrating tablets. Int J Pharm. 2018;551(1–2):141–147. Available from: https://doi.org/10.1016/j.ijpharm.2018.09.001
   PubMedGoogle Scholar
• Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing. Can. J. Cardiol. 1996;12(11):1191–1196.
   PubMedGoogle Scholar